News on the people who matter.
Healthcare

FDA approves Sanofi pill as first drug for Gaucher's neurological symptoms

The once-daily tablet beat infused enzyme therapy on coordination and cognition in a 43-patient trial.

Sanofi Chief Executive Officer Belén Garijo, in glasses and a patterned scarf, smiling in front of a geometric backdrop, in black and white
Belén Garijo in 2015, when she was CEO Healthcare at Merck KGaA. Photo by Merck (Darmstadt, Germany) / Wikimedia Commons (CC BY-SA 3.0 de), cropped and converted to black and white

The Food and Drug Administration on Wednesday approved Sanofi's Infilbray, a once-daily tablet that is the first treatment for the neurological symptoms of Type 3 Gaucher disease, a rare inherited disorder that harms the brain as well as the body.

Doctors have been able to manage the disease's effects on organs such as the liver and spleen, but no approved therapy reached its toll on the nervous system: worsening balance, coordination, speech, memory and thinking. Infilbray, known generically as venglustat, is built to cross the blood-brain barrier. The approval also gives Sanofi a new product as it braces for patent expiration on Dupixent, its top-selling drug, BioPharma Dive reported.

The label covers adults and children who weigh at least 15 kilograms, or about 33 pounds. The FDA reviewed the application on a priority basis and had granted it orphan drug status. The approval went to Genzyme Corporation, the rare-disease business Sanofi bought in 2011.

Glass entrance of a Genzyme office building with the address 500 Kendall Street and the Genzyme logo above revolving doors
Genzyme's building at 500 Kendall Street in Cambridge, Mass., in 2007. Sanofi bought Genzyme in 2011. Photo by Tim Pierce / Wikimedia Commons (public domain), cropped

Gaucher disease stems from a missing or faulty enzyme, which lets fatty molecules called glucosphingolipids pile up in tissue. In the Type 3 form those molecules also collect in the central nervous system, where they drive inflammation. Infilbray inhibits an enzyme called glucosylceramide synthase to curb that buildup, rather than supplying the missing enzyme the way infused therapies do.

Acting FDA Commissioner Kyle Diamantas said the drug's ability to reach the brain "means it can get to the source of the buildup driving the neurological symptoms".

The approval rests on a phase 3 trial called LEAP2MONO that enrolled 43 patients aged 12 and older. Each had spent at least three years on enzyme replacement therapy and reached treatment goals for the disease outside the brain. Patients were randomly assigned to oral Infilbray or to intravenous imiglucerase, an enzyme replacement, every two weeks. Both groups took a matching placebo of the other drug so neither doctors nor patients knew who got what.

After 52 weeks, patients on Infilbray did better on a combined measure of movement and cognition, according to Sanofi's announcement. The score blended a four-item version of a standard ataxia rating scale with a neuropsychological test battery. Sanofi said the advantage over imiglucerase was statistically significant, with a p-value of 0.0137.

Pramod Mistry, director of the Yale Lysosomal Disease Center and Gaucher Disease Treatment Center, said in the company's statement that physicians could treat the disease's systemic effects "while the neurological manifestations remained beyond the reach of available therapies".

The drug carries warnings for suicidal thoughts and behavior, clouding of the eye's lens in children and possible harm to a fetus. In the trial's primary analysis, diarrhea, an enlarged spleen and nausea each occurred in 14% of the 21 patients on Infilbray, against 5% or less of the 22 patients on imiglucerase. Depression was reported in 10% of the Infilbray group and in none of the comparison group. Children taking the drug will need an eye exam before treatment and once a year after that.

Venglustat had a long road to market. It failed in clinical tests for Parkinson's disease, a rare kidney condition, the lysosomal disorder GM2 gangliosidosis and, most recently, Fabry disease, according to BioPharma Dive. Before this approval, the drug had also collected breakthrough therapy, rare pediatric disease and fast-track designations in the U.S.

The approval comes in the first year of Belén Garijo's tenure as chief executive. Garijo, a physician, took charge on May 1 after running Merck KGaA, and she knows the business the drug came from. As a senior vice president at Sanofi-Aventis, Garijo led the integration of Genzyme after Sanofi acquired it, according to her company biography.

Expectations for the drug's revenue are limited. RBC Markets analyst Trung Huynh wrote in a September client note that sales expectations are modest and that a few rare-disease successes will not be enough to offset the coming loss of Dupixent revenue, BioPharma Dive reported. Sanofi has not disclosed a price. A spokesperson told the outlet that pricing would weigh clinical value against existing treatments, the effect on overall health-care costs, quality of life and affordability across the system.

Infilbray is still under review for Type 3 Gaucher disease in the European Union, Japan and other markets, and Sanofi plans more submissions worldwide in 2026 and 2027. An open-label extension of LEAP2MONO is continuing, and the company said it will present those results when they are available.

Sources

  1. Food and Drug Administration · https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease
  2. BioPharma Dive reported · https://www.biopharmadive.com/news/sanofi-fda-infilbray-venglustat-approve-gaucher/875167/
  3. Sanofi's announcement · https://www.news.sanofi.us/2026-11-18-Sanofis-Infilbray-approved-in-the-US-as-the-first-medicine-to-treat-neurological-manifestations-of-Type-3-Gaucher-disease
  4. Belén Garijo · https://www.sanofi.com/en/our-company/governance/executive-committee/belen-garijo
  5. FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease (FDA press announcement, Nov. 18, 2026) · https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease
  6. Sanofi's Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease (Sanofi press release) · https://www.news.sanofi.us/2026-11-18-Sanofis-Infilbray-approved-in-the-US-as-the-first-medicine-to-treat-neurological-manifestations-of-Type-3-Gaucher-disease
  7. Sanofi gains FDA clearance for Gaucher disease pill (BioPharma Dive) · https://www.biopharmadive.com/news/sanofi-fda-infilbray-venglustat-approve-gaucher/875167/
  8. Executive Committee: Belen Garijo, Chief Executive Officer (Sanofi) · https://www.sanofi.com/en/our-company/governance/executive-committee/belen-garijo
  9. Belen Garijo to become Chief Executive Officer of Sanofi (Sanofi press release, Feb. 12, 2026) · https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-12-06-30-00-3236866

Corrections: team@1nfluenc3.com

How we source and correct: Editorial Standards. Spot an error? Corrections.